康诺芬-66通过卡帕-阿片类受体产生局部受限的抗受体,副作用有限
Kangtai Xu1, Mengna Zhang1, Dan Chen1
1Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, State Key Laboratory of Veterinary Etiological Biology College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, PR China.
Neuropharmacology
|September 14, 2024
概括
康诺芬-66是一种新的卡帕阿片类受体 (KOR) 激动剂,有效地缓解疼痛,副作用最小. 这种局限于周围的化合物显示出开发新的止痛药而没有中枢神经系统不良影响的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 有效的疼痛管理仍然是一个挑战,需要无中央不良影响的止痛药.
- 局部限制的卡帕阿片类受体 (KOR) 激动剂为向性疼痛缓解提供了潜在的解决方案.
- 康诺芬T是一种已知的选择性KOR激动剂.
研究的目的:
- 在药理学上描述Conorphin-66,这是Conorphin T.的新型类似物.
- 为了评估康诺芬-66的疗效,选择性和副作用概况,作为一个局限的KOR激动剂.
- 要将康诺芬-66与参考化合物CR845进行比较.
主要方法:
- 在体外功能测试以评估KOR激活和信号偏差.
- 在小鼠疼痛模型 (尾巴,术后,甲,内脏疼痛) 中进行的体内抗受试研究.
- 对抗性研究以确定镇痛效应的调解;副作用的评估 (镇静,焦虑生成,抑郁,尿液,抗活性).
主要成果:
- 康诺芬-66选择性地激活了KOR,具有弱的β-arrestin2信号偏差.
- 在小鼠模型中观察到强烈的抗受体,ED50值在0.02至3.28μmol/kg之间.
- 止痛作用主要由外周KOR介导,并且在8天内观察到非耐受性.
- 康诺芬-66缺乏镇静,焦虑和抑郁效应,但表现出利尿活性,与CR845不同.
结论:
- 康诺芬-66是一种强大的,局限于周围的KOR激动剂,具有显著的抗生素性质.
- 它表现出有利的副作用概况,缺乏与传统止痛药相关的中心不良影响.
- 康诺芬-66代表了开发具有更高安全性的新型疼痛治疗药物的有希望的候选人.
相关概念视频
Opioid Receptors: Overview
588
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
588
Analgesia and Pain Management
552
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
552
Opioid Analgesics: Synthetic and Semisynthetic Opioids
251
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
251
Opioid Analgesics: Morphine and Other Natural Cogeners
192
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
192
Nociception
27.8K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154


